New drug combo shows promise for kids with brain cancer

NCT ID NCT05081180

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 31 times

Summary

This early-stage study tests two drugs, avelumab and lenvatinib, together in children with certain types of brain tumors. The goal is to find safe doses and see if the combination can slow tumor growth. The study involves 17 children whose tumors have worsened after prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique

    Angers, France

  • CHU Sainte-Justine

    Montreal, Canada

  • Hôpital de la Timone

    Marseille, France

  • Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris

    Paris, France

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • The Hospital for Sick Children

    Toronto, Canada

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

Conditions

Explore the condition pages connected to this study.